Translatable efficacy & safety testing of mAb, bispecific, & CAR T therapies

In this webinar, Dr. Brian Soper, Senior Scientific Engagement Manager at The Jackson Laboratory, will delve into preclinical data that demonstrates how immune humanized platforms can revolutionize lead optimization and safety data sets in the context of IND applications. He will highlight the significant role of monoclonal antibody-based human immune modulation in enhancing therapeutic outcomes. Additionally, he will explore the donor-specific differences in bispecific antibody-mediated tumor efficacy and cytokine release, shedding light on personalized treatment approaches. Finally, he will discuss the advancements in CAR T cell-mediated tumor efficacy and safety, presenting compelling data that showcases the potential of this groundbreaking technology.

Key learning objectives

• Explore the role of monoclonal antibody-based human immune modulation in enhancing therapeutic outcomes
• Discover the donor-specific differences in bispecific antibody-mediated tumor efficacy and cytokine release, shedding light on personalized treatment approaches
• Learn about the advancements in CAR T cell-mediated tumor efficacy and safety

Who should attend?

• Those working in preclinical development, with animal models, with a focus on oncology.

Certificate of attendance

All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.